Drugs / IMSA101
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06026254 | Sep 2023 → Sep 2025 overdue | cancer | ImmuneSensor Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04020185 | Sep 2019 → Sep 2023 | cancer | ImmuneSensor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06601296 | Apr 2025 → Oct 2027 expected | renal cell carcinoma | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05846659 | Jul 2023 → Nov 2024 | — | ImmuneSensor Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05846646 | Jun 2023 → Sep 2024 | — | ImmuneSensor Therapeutics Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMSA101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06026254 ↗ |
| Action | Activate | “IMSA101 is a small molecule analog of cGAMP and a potent STING agonist.” PMID 40533265 ↗ Jun 2025 |
| Modality | Small molecule | “IMSA101 is a small molecule analog of cGAMP and a potent STING agonist.” PMID 40533265 ↗ Jun 2025 |
| Route | Other | “IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.” NCT04020185 ↗ |